TB-500 β Complete Research Guide (2026)
Last updated 2026-06-25
TL;DR
A synthetic peptide related to thymosin beta-4, a naturally occurring actin-regulating protein. Studied in preclinical models of tissue repair; human clinical evidence is limited.
What is TB-500?
TB-500 is a synthetic peptide marketed as related to Thymosin Beta-4 (TΞ²4), a naturally occurring 43-amino-acid actin-regulating protein. The peer-reviewed literature studies Thymosin Beta-4 itself; "TB-500" is the research-chemical label applied to synthetic material sold for this purpose.
As with BPC-157, the strongest evidence is preclinical. A small number of early-phase human trials of Thymosin Beta-4 exist (for venous ulcers), but there is no approved human product and no large confirmatory trial for the indications TB-500 is marketed for.
Thymosin Beta-4 / TB-500 appears on the WADA Prohibited List and is not approved for human use.
How does TB-500 work?
Thymosin Beta-4 is a major intracellular actin-sequestering protein. In repair models it down-regulates inflammatory chemokines and cytokines while promoting cell migration, angiogenesis and cell survival.
In rodent wound models, topical or intraperitoneal TΞ²4 increased re-epithelialisation and stimulated keratinocyte migration several-fold. [INFOGRAPHIC: Thymosin Beta-4 actin regulation and cell migration]
What does the research say about TB-500?
- In a rat wound model, Thymosin Beta-4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 versus saline, and stimulated keratinocyte migration two- to three-fold. [1]
- In aged and young rodents, TΞ²4 enhanced new blood-vessel formation and accelerated wound repair. [4]
- In a diabetic (db/db) mouse burn model, TΞ²4 improved wound closure and vascularisation while reducing RAGE expression. [5]
Clinical research & studies
The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.
- [1] Thymosin beta4 accelerates wound healing β Malinda KM et al., J Invest Dermatol 1999. (animal (rat) + in-vitro)
- [2] Thymosin beta-4 and venous ulcers: a European prospective, randomized study on safety, tolerability and healing β Guarnera G et al., Ann N Y Acad Sci 2007. (human RCT (early-phase, topical))
- [3] Animal studies with thymosin beta-4, a multifunctional tissue repair and regeneration peptide β Philp D et al., Ann N Y Acad Sci 2010. (review (animal data))
- [4] Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development β Philp D et al., Mech Ageing Dev 2004. (animal (rodent))
- [5] Thymosin beta 4 improves dermal burn wound healing via downregulation of RAGE in db/db mice β Kim S et al., Biochim Biophys Acta 2014. (animal (diabetic mouse burn))
Dosing context
Published animal studies use topical, intravenous, intraperitoneal or subcutaneous routes at per-kilogram rodent doses β not a human protocol.
This is not medical advice or a usage recommendation. No validated human therapeutic dose exists for the marketed uses.
Side effects & safety profile
Human safety data are limited to early-phase trials. A European double-blind, placebo-controlled study evaluated topical Thymosin Beta-4 in venous ulcers primarily for safety and tolerability rather than definitive efficacy.
No reliable human pharmacokinetic study establishes a plasma half-life for TB-500; circulating half-life figures should be treated as unverified.
Because TB-500 is WADA-prohibited, competitive athletes face anti-doping consequences regardless of formulation.
Stacking & combinations
TB-500 is often paired with BPC-157 in recovery discussion, but no controlled human study has evaluated the combination. Combination claims are unverified.
Finding TB-500 vendors
Finding TB-500 vendors
This is an independent, neutral directory β we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.
Choose your country
We never list placeholder vendors. Pick your country to see neutral regulatory context.
User reviews
No reviews yet
Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews β we never fabricate ratings.
Frequently asked questions
TB-500 is marketed as related to Thymosin Beta-4. Published research studies Thymosin Beta-4; "TB-500" is the research-chemical label for synthetic material sold for that purpose.
References
- [1] Thymosin beta4 accelerates wound healing β Malinda KM et al., J Invest Dermatol 1999. PMID: 10469335. View sourceStudy: animal (rat) + in-vitroTopical or i.p. TΞ²4 increased re-epithelialisation 42β61% and stimulated keratinocyte migration 2β3-fold.
- [2] Thymosin beta-4 and venous ulcers: a European prospective, randomized study on safety, tolerability and healing β Guarnera G et al., Ann N Y Acad Sci 2007. PMID: 17495250. View sourceStudy: human RCT (early-phase, topical)One of the few human RCTs of TΞ²4; a safety/tolerability and healing-enhancement evaluation.
- [3] Animal studies with thymosin beta-4, a multifunctional tissue repair and regeneration peptide β Philp D et al., Ann N Y Acad Sci 2010. PMID: 20536453. View sourceStudy: review (animal data)TΞ²4 down-regulates inflammatory mediators and promotes migration, angiogenesis and cell survival across tissue types.
- [4] Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development β Philp D et al., Mech Ageing Dev 2004. PMID: 15037013. View sourceStudy: animal (rodent)Enhanced new blood-vessel formation and accelerated wound repair in young and aged rodents.
- [5] Thymosin beta 4 improves dermal burn wound healing via downregulation of RAGE in db/db mice β Kim S et al., Biochim Biophys Acta 2014. PMID: 25230158. View sourceStudy: animal (diabetic mouse burn)Improved wound closure and vascularisation while reducing RAGE expression.